Halozyme Therapeutics: 2Q Earnings Snapshot
SAN DIEGO (AP) _ Halozyme Therapeutics Inc. (HALO) on Tuesday reported a loss of $14.6 million in its second quarter.
On a per-share basis, the San Diego-based company said it had a loss of 10 cents.
The results topped Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss of 17 cents per share.
The biopharmaceutical company posted revenue of $39.1 million in the period, missing Street forecasts. Three analysts surveyed by Zacks expected $39.5 million.
Halozyme Therapeutics expects full-year revenue in the range of $205 million to $215 million.
Halozyme Therapeutics shares have increased 17% since the beginning of the year. In the final minutes of trading on Tuesday, shares hit $17.15, a decline of almost 2% in the last 12 months.